Mangalam Drugs

Why is Mangalam Drugs and Organics Ltd falling/rising?

As of 07-Aug, the stock price of Mangalam Drugs and Organics Ltd is currently rising at 27.02, but it has been underperforming with a year-to-date decline of 2.07%. Despite today's increase, the stock is trading below its moving averages and has seen a significant drop in investor participation, indicating ongoing challenges.

As of 07-Aug, the stock price of Mangalam Drugs and Organics Ltd is rising, currently at 27.02, with a change of 0.16 (0.6%) upward. This increase comes after a trend reversal where the stock has gained following two consecutive days of decline. Despite this positive movement today, the stock has been underperforming over various periods, with a year-to-date decline of 2.07% compared to a 7.89% drop in the benchmark Sensex. <BR><BR>However, it is important to note that the stock is trading below its moving averages across multiple time frames, indicating a longer-term downward trend. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 38.98% against the 5-day average, suggesting reduced interest from investors. Overall, while there is a slight rise in the stock price today, the broader context shows ongoing challenges for Mangalam Drugs and Organics Ltd.

Which are the latest news on Mangalam Drugs?

When is the next results date for Mangalam Drugs and Organics Ltd?

The next results date for Mangalam Drugs and Organics Ltd is 12 August 2026.

The next results date for Mangalam Drugs and Organics Ltd is scheduled for 12 August 2026.

How big is Mangalam Drugs?

As of 10th June, Mangalam Drugs and Organics Ltd has a market capitalization of 46.00 Cr, with recent net sales of 232.56 Cr and a net profit loss of 44.41 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Mangalam Drugs and Organics Ltd has a market capitalization of 46.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 232.56 Cr, while the sum of Net Profit for the same period reflects a loss of 44.41 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 148.98 Cr, and Total Assets amount to 366.42 Cr.

Who are in the management team of Mangalam Drugs?

The management team of Mangalam Drugs includes Govardhan M Dhoot (Chairman & Managing Director), Brijmohan Dhoot (Whole-time Director), Rukmesh P. Dhandhania, Nidhi S. Mundada, and Praveen Saxena (Independent Directors), Jayant Barde (Company Secretary & Compliance Officer), and Rakesh K. Milwani (Director). They oversee the company's strategic direction and governance.

The management team of Mangalam Drugs includes the following individuals:<BR><BR>1. **Govardhan M Dhoot** - Chairman & Managing Director<BR>2. **Brijmohan Dhoot** - Whole-time Director<BR>3. **Rukmesh P. Dhandhania** - Independent Director<BR>4. **Nidhi S. Mundada** - Independent Director<BR>5. **Praveen Saxena** - Independent Director<BR>6. **Jayant Barde** - Company Secretary & Compliance Officer<BR>7. **Rakesh K. Milwani** - Director<BR><BR>This team is responsible for the strategic direction and governance of the company.

Who are the peers of the Mangalam Drugs?

Peers of Mangalam Drugs include Kabra Drugs, Shelter Pharma, Veerhealth Care, Rajnish Wellness, Vista Pharma, Sandu Pharma, Murae Organisor, Roopa Industries, and ANG Lifesciences. Mangalam Drugs has below-average growth and capital structure, with a 1-year return of -65.43%.

Peers: The peers of Mangalam Drugs are Kabra Drugs, Shelter Pharma, Veerhealth Care, Rajnish Wellness, Vista Pharma, Sandu Pharma, Murae Organisor, Roopa Industries, and ANG Lifesciences.<BR><BR>Quality Snapshot: Excellent management risk is observed at Kabra Drugs and Murae Organisor, while Average management risk is found at Shelter Pharma and Rajnish Wellness. Below Average management risk is noted at Veerhealth Care, Mangalam Drugs, Vista Pharma, Sandu Pharma, Roopa Industries, and ANG Lifesciences. For growth, Excellent growth is seen at Kabra Drugs and Roopa Industries, Good growth at Shelter Pharma and Murae Organisor, Average growth at Veerhealth Care, and Below Average growth at Mangalam Drugs, Rajnish Wellness, Vista Pharma, Sandu Pharma, and ANG Lifesciences. In terms of Capital Structure, Excellent capital structure is present at Shelter Pharma, Good capital structure at Sandu Pharma, and Below Average capital structure at Kabra Drugs, Mangalam Drugs, Rajnish Wellness, Vista Pharma, Murae Organisor, Roopa Industries, and ANG Lifesciences.<BR><BR>Return Snapshot: Kabra Drugs has the highest 1-year return at 86.81%, while Murae Organisor has the lowest at -83.76%. Mangalam Drugs' 1-year return of -65.43% is significantly lower than Kabra Drugs but higher than Murae Organisor. Additionally, the six-month return is negative for Rajnish Wellness, Vista Pharma, Murae Organisor, and ANG Lifesciences.

What does Mangalam Drugs do?

Mangalam Drugs and Organics Ltd manufactures organic and inorganic chemicals in the Pharmaceuticals & Biotechnology industry. As of March 2026, it reported net sales of 67 Cr and a net loss of 13 Cr, with a market cap of INR 46 Cr.

Overview:<BR>Mangalam Drugs and Organics Ltd is a company engaged in the manufacture of organic and inorganic chemicals, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>History:<BR>The company was initially incorporated as 'Advent Pharma Private Limited' in 1972 and underwent several name changes, becoming Mangalam Drugs and Organics Limited in 2001. The latest reported financial results are for the quarter ending March 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 67 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: -13 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 46 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 1.02<BR>- Return on Equity: -43.09%<BR>- Price to Book: 0.43<BR><BR>Contact Details:<BR>Address: 3rd Floor Rupam Building, 239 P D Mello Road Mumbai Maharashtra : 400001<BR>Tel: 91-22-22616200/6300/8787<BR>Email: contactus@mangalamdrugs.com<BR>Website: http://www.mangalamdrugs.com

Are Mangalam Drugs and Organics Ltd latest results good or bad?

Mangalam Drugs and Organics Ltd's latest results are concerning, with a net profit loss of ₹13.42 crores in Q4 FY26, marking the fourth consecutive quarter of losses. Despite a slight improvement in net sales, the company faces significant operational challenges, reflected in a negative operating margin and a return on equity of -15.52%.

The latest results for Mangalam Drugs and Organics Ltd are quite concerning. In Q4 FY26, the company reported a net profit loss of ₹13.42 crores, which is a staggering decline of 22,466.67% year-on-year. This marks the fourth consecutive quarter of losses, totaling ₹44.41 crores for the fiscal year.<BR><BR>While net sales for Q4 FY26 were ₹67.29 crores, showing a 15.26% improvement from the previous quarter, this still represents a 7.54% decline compared to the same quarter last year. The operating margin has turned negative at -8.35%, a significant drop from a positive 13.60% in Q4 FY25. <BR><BR>Additionally, the company's return on equity (ROE) has plummeted to -15.52%, indicating severe operational and financial distress. The overall financial performance suggests that the company is struggling with fundamental issues that extend beyond typical market challenges. <BR><BR>In summary, the results indicate a deteriorating situation for Mangalam Drugs, characterized by significant losses, declining sales, and negative profitability metrics.

Should I buy, sell or hold Mangalam Drugs and Organics Ltd?

Is Mangalam Drugs overvalued or undervalued?

As of November 21, 2025, Mangalam Drugs is considered a risky investment due to its negative PE ratio of -3.75, ROE of -13.07%, and an EV to EBITDA ratio of 13.75, significantly underperforming against peers like Sun Pharma and Cipla, and has a year-to-date return of -60.33% compared to the Sensex's 9.08%.

As of 21 November 2025, the valuation grade for Mangalam Drugs has moved from very attractive to risky, indicating a significant deterioration in its financial standing. The company is currently considered overvalued based on its negative PE ratio of -3.75 and a ROE of -13.07%. Additionally, the EV to EBITDA ratio stands at 13.75, which is notably higher than some peers, suggesting that investors are paying a premium despite the company's poor performance.<BR><BR>In comparison to its peers, Mangalam Drugs' valuation metrics are starkly unfavorable. For instance, Sun Pharma has a PE ratio of 36.98 and an EV to EBITDA of 24.43, while Cipla, which is rated attractive, has a PE of 22.45 and an EV to EBITDA of 15.88. The stark contrast in these ratios highlights Mangalam Drugs' overvaluation in the current market context. Furthermore, the company's stock has significantly underperformed against the Sensex, with a year-to-date return of -60.33% compared to the Sensex's 9.08%, reinforcing the notion that Mangalam Drugs is not a favorable investment at this time.

How has been the historical performance of Mangalam Drugs?

Mangalam Drugs showed significant financial improvement from March 2024 to March 2025, with net sales decreasing to 318.23 Cr but operating profit rising to 36.33 Cr, leading to a profit after tax of 6.72 Cr. The company also experienced a strong increase in cash flow from operating activities, indicating a recovery and growth trajectory.

Answer:<BR>The historical performance of Mangalam Drugs shows a significant improvement in financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Mangalam Drugs reported net sales of 318.23 Cr, a decrease from 368.59 Cr in the previous year. Total operating income mirrored this trend, remaining at 318.23 Cr, while total expenditure excluding depreciation fell to 282.40 Cr from 351.20 Cr. This reduction in costs contributed to an operating profit (PBDIT) of 36.33 Cr, up from 17.49 Cr, reflecting a notable increase in operating profit margin from 4.73% to 11.28%. The company transitioned from a loss of 11.07 Cr in profit before tax in March 2024 to a profit of 4.79 Cr in March 2025, with profit after tax also improving from a loss of 9.07 Cr to a profit of 6.72 Cr. Earnings per share rose to 4.25 from a negative 5.73. On the balance sheet, total liabilities increased to 366.42 Cr from 333.70 Cr, while shareholder's funds grew to 148.98 Cr from 135.79 Cr. The cash flow from operating activities surged to 42.00 Cr compared to 3.00 Cr in the prior year, indicating a strong operational performance. Overall, these metrics illustrate a recovery and growth trajectory for Mangalam Drugs in the latest fiscal year.

What is the technical trend for Mangalam Drugs?

As of May 22, 2025, Mangalam Drugs shows a mildly bearish trend, with daily moving averages and weekly Bollinger Bands indicating bearish signals, despite some mildly bullish indicators from MACD, KST, and OBV, while the stock has significantly underperformed the Sensex over the past year.

As of 22 May 2025, the technical trend for Mangalam Drugs has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the weekly Bollinger Bands also showing a mildly bearish signal. The MACD on a weekly basis is mildly bullish, but the monthly perspective remains bearish, suggesting mixed signals. The KST and OBV on the weekly timeframe are mildly bullish, indicating some underlying strength, yet the overall trend remains cautious. The stock's performance over the past year shows a significant decline, underperforming the Sensex, which further supports the bearish outlook.

Who are the top shareholders of the Mangalam Drugs?

The top shareholders of Mangalam Drugs include Shri Jb Pharma Private Limited with 16.74%, individual investors with 44.55%, and two foreign institutional investors holding 0.47%. The highest public shareholder is Ashutosh Tapria at 1.91%, with 13.23% of promoter holdings pledged.

The top shareholders of Mangalam Drugs are primarily the promoters, with Shri Jb Pharma Private Limited holding the largest stake at 16.74%. Additionally, individual investors collectively own 44.55% of the shares. The company has two foreign institutional investors (FIIs) that hold a combined 0.47%. The highest public shareholder is Ashutosh Tapria, who owns 1.91% of the shares. It's worth noting that 13.2252% of the promoter holdings are pledged.

Has Mangalam Drugs declared dividend?

Yes, Mangalam Drugs and Organics Ltd declared a 5% dividend (0.5 per share) with an ex-date of December 21, 2017. However, recent performance shows no dividend returns over various periods, with total returns fluctuating significantly.

Mangalam Drugs and Organics Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 21 Dec 17<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -32.44%, the dividend return was 0%, resulting in a total return of -32.44%.<BR><BR>For the 1-year period, the price return was -20.09%, the dividend return was 0%, leading to a total return of -20.09%.<BR><BR>Over the 2-year period, the price return was -22.72%, with a dividend return of 0%, culminating in a total return of -22.72%.<BR><BR>In the 3-year period, the price return was -46.19%, the dividend return was 0%, resulting in a total return of -46.19%.<BR><BR>For the 4-year period, the price return was -40.39%, the dividend return was 0%, leading to a total return of -40.39%.<BR><BR>In the 5-year period, the price return was 32.79%, with a dividend return of 0%, resulting in a total return of 32.79%.<BR><BR>Overall, while Mangalam Drugs declared a dividend in the past, the recent performance shows no dividend returns in the last several periods, and the total returns have varied significantly, reflecting a challenging financial landscape.